| ABSTRACT Objective:To evaluate the efficacy and safety of leosimendan in the treatment of acute decompensated heart failure.Methods:85 cases with acute decompensated heart failurewere randomly divided into study group and control group. The control group were treated with conventional medicines, and the study group were given leosimendan additionally for 24h. The changes of LVEF, SV, LVEDD, LVESD, BNP, 24 h urine volume and NYHA classification were evaluated, as well as efficacy and safety. Results:The values of LVEF, BNP, 24 h urine volume and NYHA classification changed more obviously than those before treatment (P<0.05), but the SV and LVEDD produced almost no change (P>0.05). There were still significantly differences in LVEF, BNP, 24 h urine volume and NYHA classification compared between groups after treatment (P<0.05),but there were no significantly differences in SV, LVESD and LVEDD compared between two groups after treatment(P>0.05).The total effective rate was 72.09%in study group, higher than 54.77% in control group. But there was no statistical difference between the two groups(P>0.05). The rate of adverse reaction was 30.23%(13/43), higher than 11.90%(5/42) in control group (P<0.05). Conclusion: Leosimendan in the treatment of acute decompensated heart failure can significantly improve heart function, but we should pay more attention to the occurrence of low blood pressure and cardiac arrhythmias. |
